Breaking News Instant updates and real-time market news.

VYGR

Voyager Therapeutics

$10.82

0.2 (1.88%)

07:26
12/10/18
12/10
07:26
12/10/18
07:26

Voyager Therapeutics doses first patient in RESTORE-1 trial

Voyager Therapeutics announced dosing of the first patient in RESTORE-1, a Phase 2, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of VY-AADC for the treatment of Parkinson's disease in patients with motor fluctuations that are refractory to medical management.

VYGR Voyager Therapeutics
$10.82

0.2 (1.88%)

11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/18
RAJA
11/14/18
UPGRADE
RAJA
Strong Buy
Voyager Therapeutics upgraded to Strong Buy from Outperform at Raymond James
11/09/18
HCWC
11/09/18
NO CHANGE
Target $25
HCWC
Buy
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Voyager Therapeutics to $25 after the company received an addendum from the FDA indicating that the agency currently considers the Phase 2 as an exploratory study. Given the limited clinical catalysts for the stock and the significant management turnover during 2018, "the latest headwind was not well received by the Street in our view," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
11/08/18
WEDB
11/08/18
NO CHANGE
Target $18
WEDB
Outperform
Voyager Therapeutics price target lowered to $18 from $28 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Voyager Therapeutics to $18 form $28 following updated, negative FDA guidance related to its registration plan for gene therapy candidate VYAADC in patients with severe Parkinson's disease that will likely extend the program's path to registration. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

09:33
11/13/19
11/13
09:33
11/13/19
09:33
General news
Powell says 'noteworthy risks' to baseline economic outlook remain »

Federal Reserve Chairman…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$89.00

6.3 (7.62%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Recommendations
Tyson Foods analyst commentary  »

Tyson Foods price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$9.96

0.13 (1.32%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Conference/Events
eXp World Holdings management to meet with DA Davidson »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

TRPX

Therapix Biosciences

$1.41

-0.16 (-10.19%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Hot Stocks
Therapix Biosciences says Phase IIa study of THX-110 met primary endpoint »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$255.29

-0.7 (-0.27%)

09:31
11/13/19
11/13
09:31
11/13/19
09:31
Conference/Events
House Science, Space & Technology Committee to hold a hearing »

The Subcommittee on Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

EEFT

Euronet

$149.96

1.99 (1.34%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Conference/Events
Euronet management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DG

Dollar General

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Recommendations
Dollar General analyst commentary  »

Dollar General Q3 comp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

BGNE

BeiGene

$196.20

4.5 (2.35%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Downgrade
BeiGene rating change  »

BeiGene downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

DEO

Diageo

$157.94

-1.87 (-1.17%)

09:29
11/13/19
11/13
09:29
11/13/19
09:29
Conference/Events
Diageo management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DBD

Diebold

$8.10

0.025 (0.31%)

09:28
11/13/19
11/13
09:28
11/13/19
09:28
Conference/Events
Diebold management to meet with DA Davidson »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPX

Continental Building

$35.76

3.73 (11.65%)

, GMS

GMS Inc.

$30.73

0.21 (0.69%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Recommendations
Continental Building, GMS Inc., Foundation Building Materials analyst commentary  »

Continental Building…

CBPX

Continental Building

$35.76

3.73 (11.65%)

GMS

GMS Inc.

$30.73

0.21 (0.69%)

FBM

Foundation Building Materials

$21.20

0.2 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRLBF

Cresco Labs

$0.00

(0.00%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Conference/Events
Cresco Labs management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNI

Canadian National

$93.08

-0.485 (-0.52%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
Canadian National management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 21

    Nov

  • 22

    Nov

BRTX

BioRestorative Therapies

$0.00

(0.00%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
BioRestorative Therapies to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TLRY

Tilray

$21.57

-0.4 (-1.82%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Recommendations
Tilray analyst commentary  »

Tilray price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/13/19
11/13
09:25
11/13/19
09:25
General news
Fed Chair Powell goes to Capitol Hill for his JEC testimony »

Fed Chair Powell goes to…

EL

Estee Lauder

$187.89

0.63 (0.34%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 06

    Feb

BWEN

Broadwind Energy

$1.53

(0.00%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Conference/Events
Broadwind Energy management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

BLDR

Builders FirstSource

$24.75

0.4 (1.64%)

09:22
11/13/19
11/13
09:22
11/13/19
09:22
Conference/Events
Builders FirstSource management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 05

    Dec

NVFY

Nova Lifestyle

$0.54

(0.00%)

09:21
11/13/19
11/13
09:21
11/13/19
09:21
Earnings
Nova Lifestyle reports Q3 revenue $9.3M vs. $16.7M last year »

Tawny Lam, Chairperson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMN

AMN Healthcare

$60.42

0.53 (0.88%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Conference/Events
AMN Healthcare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PHOT

GrowLife

$0.00

(0.00%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Earnings
GrowLife reports Q3 revenue $2.3M vs. $1M last year »

GrowLife CEO Marco Hegyi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$28.32

-0.45 (-1.56%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Conference/Events
Aimmune management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Hot Stocks
Neoleukin Therapeutics expects cash to fund operations through 2021 »

Cash and cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:18
11/13/19
11/13
09:18
11/13/19
09:18
Earnings
Neoleukin Therapeutics reports Q3 EPS ($2.26), one est. (4c) »

"The past quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.